Tag Archives: M&A

GSK: A Rebuffed Suitor for the Moment

By Guest Blogger | Published: April 25, 2012
By Patricia Van Arnum. Last week Human Genome Sciences (HGS) rejected GlaxoSmithKline’s (GSK) unsolicited $2.59 billion bid for HGS or $13 per share.  Although rejecting GSK’s initial bid, HGS kept the door open for other suitors, including again GSK. HGS has authorized its board of directors to explore strategic alternatives for the company, including a potential sale. [...]
Posted in Deals, Guest Blog | Also tagged , , , | 1 Comment

Uncertain Outlook for Pharma and Biotech Deals Following 'Turbulent' 2011

By Guest Blogger | Published: April 18, 2012
Peter Young, President and Managing Director of international investment bank Young & Partners, looks at what lies ahead for pharma and biotech following a turbulent 2011. The business outlook for pharma companies for the rest of 2012 and beyond is mixed, as pharma companies struggle to realign themselves to a new business model that will work. [...]
Posted in Global, Guest Blog, Strategy, leadership | Also tagged , , , , | Leave a comment

Putting the M Back in M&A

By Jennifer Ringler | Published: December 13, 2011
Joe Panetta, president and CEO of BIOCOM, discusses an emerging model of M&As in which human and IP assets are valued and biotech brings expertise to Big Pharma as venture capitalist funding dwindles and patent cliffs loom large. Pharm Exec: Can you tell me about how small biotech and specialty companies have started switching from relying [...]
Posted in Agency Insight, Biotech, Deals, FDA | Also tagged , , | Leave a comment

Pharma to Flash the Cash to Counter Bleak Short-Term Outlook

By Julian Upton | Published: July 13, 2011
Nearly two-thirds of US senior pharmaceutical executives surveyed by last month foresee a ‘full economic recovery’ by the end of 2013, with more than half of these pointing to an upturn in the industry’s fortunes by the end of next year. However, 27 percent of the 100 executives interviewed by KPMG for its Industry Pulse Survey [...]
Posted in Strategy | Also tagged , , , | Leave a comment

With Cephalon Buy, Teva Bets on Brand Drugs and More In-House Innovation

By Ben Comer | Published: May 4, 2011
If commodity generics and in-licensing deals are all the rage, then Teva just strapped on a fanny pack with its $6.8 billion acquisition of Cephalon. The deal is expected to skyrocket Teva’s brand drug portfolio to $7 billion in annual sales, making Teva “not only the world’s largest generics company, but also one of the world’s [...]
Posted in Deals, Strategy | Also tagged , , , | 3 Comments